Brain Development Research Consortium

Upcoming Meeting

Image
Pregnant woman

Impact of Comorbid COVID-19 and Substance Use During Pregnancy on Fetal and Infant Development Workshop

NIDA Brain Development Research Consortium

• Wednesday, July 20th, 10 am - 5 pm ET

Numerous underlying medical conditions are associated with worse outcomes for those infected with SARS-CoV-2, including pregnancy and recent pregnancy (defined as at least 42 days following the end of pregnancy). In the short-term, SARS-CoV-2 infection in pregnant individuals increases the risk for severe illness for the individual leading to hospitalization, caesarean birth, and death as well as risks for the fetus including stillbirth, pre-term birth, and poor fetal outcomes. The long-term impact of COVID-19 illness during and following recent pregnancy is still being determined; however, recent studies point to potential effects on neurodevelopment.

Get more information and register for the meeting.

“Enhancing the science of brain development to improve drug abuse prevention, treatment and recovery”

What We Do:

The mission of the NIDA Brain Development Research Consortium is to foster translational science on brain development, cognition, behavior and functioning to advance the understanding of drug abuse and addiction, prevention, treatment and recovery within the scientific mission areas of NIDA.

The Brain Development Research Consortium includes a multidisciplinary group of NIDA staff representing diverse programs and offices working to enhance basic and clinical research on drug abuse by examining neurodevelopment, addiction and the complex interplay of contextual, behavioral, and genetic factors.

Research Areas of Interest:

  • neonatal, fetal and pediatric biomarkers, drug exposure, abstinence and treatment;
  • emotional regulation, attention, functioning and brain plasticity;
  • critical developmental periods and pathways for vulnerability/resilience to drug abuse;>
  • novel drug abuse prevention in diverse settings;
  • drug abuse and psychiatric comorbidities across the life course;
  • addiction, developmental risk and HIV;
  • behavioral and pharmacological treatments for substance abuse in adolescence;
  • pediatric and adolescent multisite clinical trials; and
  • drug abuse recovery for youths and young adults.

Contact:

Meetings:

Links of Interest to Multisite Research and Tools:

NIDA Related Publication Resources:

Past BDRC Funding Announcements